Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

Blood

Volumn 117, Issue 17, 2011, Pages 4519-4529

  Alduaij, Waleed ^a   Ivanov, Andrei ^b   Honeychurch, Jamie ^a   Cheadle, Eleanor J ^a   Potluri, Sandeep ^a   Lim, Sean H ^c   Shimada, Kazuyuki ^c   Chan, Claude H T ^c   Tutt, Alison ^c   Beers, Stephen A ^c   Glennie, Martin J ^c   Cragg, Mark S ^c   Illidge, Tim M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CASPASE; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PROTEIN BCL 2; RITUXIMAB; TRASTUZUMAB;

ACTIN POLYMERIZATION; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CELL ADHESION; CELL DEATH; CELL VIABILITY; CLEARANCE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPHOMA CELL; LYSOSOME; LYSOSOME MEMBRANE; MALE; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROTEIN ENGINEERING;

EID: 79955979273     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-296913     Document Type: Article

References (52)

1. Coiffier B, Lepage E, Briere J, et al. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
2. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706-714. (Pubitemid 47078732)
3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
4. van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010;47(2):199-210.
5. Lim SH, Beers SA, French RR, Johnson PWM, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95(1):135-143.
6. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6(4):443-446. (Pubitemid 30208162)
7. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112(4):1205-1213.
8. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940-3947. (Pubitemid 46606207)
9. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7):2738-2743. (Pubitemid 38393032)
10. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171(3):1581-1587. (Pubitemid 36900094)
11. Beers SA, Chan CHT, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-4177.
12. Weng W-K, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001;98(5):1352-1357.
13. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111(3):1456-1463. (Pubitemid 351213433)
14. Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009;114(26):5322-5330.
15. de Haij S, Jansen JH, Boross P, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010;70(8):3209-3217.
16. Chan HTC, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480-5489. (Pubitemid 37139867)
17. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
18. Sehn LH, Assouline SE, Stewart DA, et al. A phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed/refractory CD20+ malignant disease [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 934.
19. Salles A, Morchhauser F, Thieblemont C, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated patients- first results from a phase II study in patients with relapsed/refractory indolent NHL (INHL) [abstract]. Haematologica. 2010;95(suppl 2):Abstract 558.
20. Friess T, Gerdes C, Nopora A, et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, mediates superior efficacy in a variety of NHL xenograft models in comparison to rituximab [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110(11):Abstract 2338.
21. Penninger JM, Crabtree GR. The actin cytoskeleton and lymphocyte activation. Cell. 1999;96(1):9-12. (Pubitemid 29044148)
22. Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143- 2159.
23. Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer. 2005;5(11):886-897. (Pubitemid 41746033)
24. Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res. 2008;14(15):4925-4934.
25. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab′ gamma fragments. J Immunol. 1987;139(7):2367-2375. (Pubitemid 17152136)
26. Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Lukman H, Illidge TM. Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci. 2003;116(20):4095-4106. (Pubitemid 37337084)
27. Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med. 2004;200(4):425-435. (Pubitemid 39121900)
28. Kirkegaard T, Roth AG, Petersen NH, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature. 2010;463(7280):549-553.
29. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab′)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51(1):15-24. (Pubitemid 34158519)
30. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971-16984.
31. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against nodn-Hodgkin lymphomas. Blood. 2004;104(6):1793-1800. (Pubitemid 39202289)
32. Cerisano V, Aalto Y, Perdichizzi S, et al. Molecular mechanisms of CD99-induced caspasein-dependent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene. 2004;23(33):5664-5674. (Pubitemid 39093044)
33. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
34. Teeling JL, Mackus WJM, Wiegman LJJM, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371. (Pubitemid 43939148)
35. Niederfellner GJ, Lammens A, Schwaiger M, et al. Crystal structure analysis reveals that the novel type II anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundamentally different way [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 3726.
36. van der Kolk LE, Evers LM, Omene C, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia. 2002;16(9):1735-1744.
37. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-1652. (Pubitemid 28110329)
38. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174.
39. Kansas GS, Tedder TF. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol. 1991;147(12):4094-4102.
40. Barbier S, Chatre L, Bras M, et al. Caspasein-dependent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton. Haematologica. 2009;94(4):507-517.
41. Arana E, Vehlow A, Harwood NE, et al. Activation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunologicalsynapse formation. Immunity. 2008;28(1):88-99.
42. Gronbaek K, Jaattela M. Engaging the lysosomal compartment to combat B cell malignancies. J Clin Invest. 2009;119(8):2133-2136.
43. Merle-Beral H, Barbier S, Roue G, Bras M, Sarfati M, Susin SA. Caspase-independent type III PCD: a new means to modulate cell death in chronic lymphocytic leukemia. Leukemia. 2008;23(5):974-977.
44. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27(50):6434-6451.
45. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006. 2006;107(11):4207-4213. (Pubitemid 43801342)
46. Awan FT, Kay NE, Davis ME, et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood. 2009;113(3):535-537.
47. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437-443. (Pubitemid 46655595)
48. Schlette EJ, Admirand J, Wierda W, et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma. 2009;50(10):1597-1605.
49. Lian J, Wu X, He F, et al. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ. 2011;18(1):60-71.
50. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010;120(4):1310-1323.
51. Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res. 2007;67(5):2217-2225. (Pubitemid 46424241)
52. Alduaij W, Potluri S, Ivanov A, et al. New-generation anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 725.